Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (7215)	10/23/2002 9:14:28 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

>>Pfizer Wins Viagra Patent, Moves to Block Competition<< This is very interesting and significant. I couldn't find the PFE patent after a quick search. Anyone else? Interestingly, I did find another use patent in the field, this time by Lilly/Icos: United States Patent 6,451,807 Emmick , et al. September 17, 2002 Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor Abstract The present invention relates to highly selective phosphodiesterase (PDE) enzyme inhibitors and to their use in methods of treating sexual dysfunction in individuals suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction. A broad use patent like the one that PFE claims would have a huge effect. Essentially all "me-too" drugs would be blocked, including ones that might be substantially better. From a public policy perspective, this situation cries out for compulsory licensing at a reasonable royalty. Peter